Details for New Drug Application (NDA): 014602
✉ Email this page to a colleague
The generic ingredient in CELESTONE SOLUSPAN is betamethasone acetate; betamethasone sodium phosphate. There are sixty-six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the betamethasone acetate; betamethasone sodium phosphate profile page.
Summary for 014602
| Tradename: | CELESTONE SOLUSPAN |
| Applicant: | Organon |
| Ingredient: | betamethasone acetate; betamethasone sodium phosphate |
| Patents: | 0 |
Pharmacology for NDA: 014602
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Suppliers and Packaging for NDA: 014602
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CELESTONE SOLUSPAN | betamethasone acetate; betamethasone sodium phosphate | INJECTABLE;INJECTION | 014602 | NDA | Organon LLC | 78206-118 | 78206-118-01 | 1 VIAL, MULTI-DOSE in 1 BOX (78206-118-01) / 5 mL in 1 VIAL, MULTI-DOSE |
| CELESTONE SOLUSPAN | betamethasone acetate; betamethasone sodium phosphate | INJECTABLE;INJECTION | 014602 | NDA | Sportpharm, Inc. dba Sportpharm | 85766-070 | 85766-070-05 | 1 VIAL, MULTI-DOSE in 1 BOX (85766-070-05) / 5 mL in 1 VIAL, MULTI-DOSE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 3MG/ML;EQ 3MG BASE/ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | AB | RLD: | Yes | ||||
Expired US Patents for NDA 014602
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Organon | CELESTONE SOLUSPAN | betamethasone acetate; betamethasone sodium phosphate | INJECTABLE;INJECTION | 014602-001 | Approved Prior to Jan 1, 1982 | 3,485,854 | ⤷ Get Started Free |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
